Amedisys FY2024 EPS Estimate Decreased by Leerink Partnrs

Amedisys, Inc. (NASDAQ:AMED - Free Report) - Investment analysts at Leerink Partnrs cut their FY2024 earnings per share (EPS) estimates for shares of Amedisys in a research note issued on Wednesday, January 29th. Leerink Partnrs analyst W. Mayo now anticipates that the health services provider will post earnings of $4.31 per share for the year, down from their previous estimate of $4.51. The consensus estimate for Amedisys' current full-year earnings is $4.40 per share. Leerink Partnrs also issued estimates for Amedisys' Q4 2024 earnings at $0.96 EPS, Q1 2025 earnings at $1.20 EPS, Q2 2025 earnings at $1.50 EPS, Q3 2025 earnings at $1.17 EPS, Q4 2025 earnings at $1.04 EPS, FY2025 earnings at $4.90 EPS, Q1 2026 earnings at $1.24 EPS, Q2 2026 earnings at $1.54 EPS, Q3 2026 earnings at $1.20 EPS and Q4 2026 earnings at $1.08 EPS.

Amedisys (NASDAQ:AMED - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The health services provider reported $1.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.19 by ($0.19). The firm had revenue of $587.67 million during the quarter, compared to analyst estimates of $586.75 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. Amedisys's quarterly revenue was up 5.7% on a year-over-year basis. During the same period last year, the firm earned $0.98 EPS.

Amedisys Trading Up 0.4 %

NASDAQ:AMED traded up $0.41 on Friday, reaching $92.56. The company's stock had a trading volume of 115,190 shares, compared to its average volume of 303,564. Amedisys has a 1-year low of $82.15 and a 1-year high of $98.95. The business's 50-day moving average price is $89.43 and its two-hundred day moving average price is $93.92. The firm has a market cap of $3.03 billion, a PE ratio of 36.77, a PEG ratio of 1.82 and a beta of 0.73. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19.

Hedge Funds Weigh In On Amedisys

Several institutional investors and hedge funds have recently modified their holdings of AMED. National Bank of Canada FI lifted its stake in Amedisys by 119.0% in the third quarter. National Bank of Canada FI now owns 55,592 shares of the health services provider's stock valued at $5,365,000 after buying an additional 30,213 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Amedisys by 1.3% during the third quarter. Geode Capital Management LLC now owns 567,105 shares of the health services provider's stock worth $54,746,000 after acquiring an additional 7,071 shares during the period. Quarry LP bought a new stake in Amedisys in the 3rd quarter valued at $2,569,000. Charles Schwab Investment Management Inc. boosted its stake in Amedisys by 2.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 346,082 shares of the health services provider's stock worth $33,400,000 after purchasing an additional 9,004 shares during the period. Finally, Holocene Advisors LP increased its holdings in Amedisys by 391.4% during the 3rd quarter. Holocene Advisors LP now owns 79,036 shares of the health services provider's stock worth $7,628,000 after purchasing an additional 62,953 shares in the last quarter. 94.36% of the stock is currently owned by institutional investors and hedge funds.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.